$COR

DURCAN DERMOT MARK purchased $1.1M of COR

DURCAN DERMOT MARK purchased 4,000 shares of Cencora, Inc. (COR) at $274.19 ($1.10M total) on 2026-06-18.

Original reporting
SEC EDGAR · DURCAN DERMOT MARK
Published Jun 22, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$COR
Bullish
medium confidence
Mentioned
$COR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (shares, price, total value, post-transaction holdings). This can slightly influence sentiment but does not change fundamentals in the text.

02

Market read

Traders may note the insider buy, but the disclosure alone is unlikely to drive a sustained repricing without additional company-specific catalysts.

03

What to watch

No context on whether the purchase was part of a broader pattern, compensation-related activity, or personal liquidity needs; also no 10b5-1 plan is stated, but that alone doesn’t confirm conviction.

Relevance 7/10Novelty 5/10Timing: after-hours/filing timestamp (2026-06-22) for a 2026-06-18 purchase

Background

The article is an SEC Form 4 insider transaction disclosure for Cencora (COR).

Company-level read

Ticker impact

$CORBullishMedium confidence
Context

Cencora director Durcan Dermot Mark filed a Form 4 open-market purchase of 4,000 shares at $274.19 on 2026-06-18.

Expected impact

Likely limited near-term impact; any effect would be small and fade unless followed by additional disclosures or operational news.

Evidence & confidence

The filing is a routine director open-market purchase (no 10b5-1 plan), but the article provides no new company fundamentals, guidance, or event beyond the transaction details.

Market effects

No sector-level read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Director purchases can be discretionary and may not reflect a new thesis; the disclosed size may be too small to matter for valuation.

Key entities

  • Cencora, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • DURCAN DERMOT MARK

    Director who purchased 4,000 shares of COR open-market on 2026-06-18.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORHighAI 8/10

Is Cencora Stock Underperforming the Dow?

Cencora (COR), a $61.6B pharmaceutical distributor, is down 14% from its 52-week high but up 18.5% over 3 months, outperforming the Dow. Its Q3 revenue missed estimates, but adjusted EPS beat forecasts. Analysts rate it a 'Strong Buy' with a $366.50 target, implying 12.9% upside. Peer Cardinal Health (CAH) gained 60% over the past year.

$PGNYMedAI 8/10

Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.

$CORHighAI 8/10

Why Cencora (COR) Is Getting Attention Today

Cencora (COR) reported Q3 2026 adjusted EPS of $4.48, beating estimates, and raised full-year guidance. Shares fell 1.86% to $330.95 but gained 20.75% over 90 days. The company's long-term returns are strong, with a 1-year return of 14.01% and a 5-year return of 183.23%. Analysts suggest fair value at $372.58, citing digital investments and healthcare trends.

$MCKMedAI 8/10

and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits.

McKesson (MCK) and Cencora (COR) are positioned to benefit from certain drug price inflation due to contractual provisions. McKesson reported $403.4B revenue and $39.11 EPS for fiscal 2026, with Q1 2027 revenue at $105.4B and EPS at $9.93. Cencora generated $321.3B revenue in fiscal 2025, with Q2 revenue at $78.4B and EPS at $4.75. Both companies have raised EPS forecasts.

$MCKHighAI 9/10

With Price-Increase Clauses, These Two Drug Distributors Can Withstand ‘Trumpflation’

McKesson (MCK) and Cencora (COR) benefit from drug price increases due to inflation-based compensation clauses. McKesson reported $403.4B revenue in 2026, up 12%, and raised EPS guidance. Cencora posted $321.3B revenue in 2025, up 3.8%, and increased EPS guidance. Both companies' contracts allow gains from manufacturer price hikes, but risks include regulation and cost pressures.

$CVSMedAI 8/10

Health Insurance Providers Stocks Q2 Teardown: Clover Health (NASDAQ:CLOV) Vs The Rest

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.